Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
NCT ID NCT07701681
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of two drugs—sacituzumab tirumotecan (a targeted chemotherapy) and tagitanlimab (an immunotherapy)—as a second-line treatment for people with advanced esophageal squamous cell carcinoma or gastric/gastroesophageal junction adenocarcinoma. The study enrolls about 75 adults whose cancer has worsened after initial treatment. Researchers will measure how many patients' tumors shrink or disappear and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two drugs: sacituzumab tirumotecan (an antibody-drug conjugate) and tagitanlimab (an immunotherapy)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced esophageal or stomach cancers that have progressed after initial therapy.
- What could go wrong
- This is an early-phase, single-arm study with a small number of participants, so results may not be definitive. The combination may cause significant side effects, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a less extensive stomach surgery preserve appetite better?
- Can early tumor response guide smarter cancer treatment?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Breath of life: new test could sniff out gut cancers before they spread